疫苗设计达到原子水平。
Vaccine design reaches the atomic level.
机构信息
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Sci Transl Med. 2011 Jul 13;3(91):91ps29. doi: 10.1126/scitranslmed.3002807.
Abstract
The genetic diversity of pathogens presents a challenge to the development of broadly effective vaccines. In this issue, Scarselli et al. combine atomic-level structural information with genomics and classical vaccinology to design a single immunogen that elicits protective immunity against more than 300 natural variants of the bacterial pathogen meningococcus B. This accomplishment provides a glimpse of the power of structure-based vaccine design to create immunogens capable of eliciting protective responses against genetically diverse pathogens.
摘要
病原体的遗传多样性对广泛有效的疫苗的开发提出了挑战。在本期杂志中，Scarselli 等人将原子水平的结构信息与基因组学和经典疫苗学相结合，设计了一种单一的免疫原，该免疫原能够针对脑膜炎球菌 B 的 300 多种天然变体引发保护性免疫。这一成就让人们看到了基于结构的疫苗设计的威力，这种设计能够创造出能够针对遗传多样性病原体引发保护性反应的免疫原。
相似文献
1
Vaccine design reaches the atomic level.疫苗设计达到原子水平。
Sci Transl Med. 2011 Jul 13;3(91):91ps29. doi: 10.1126/scitranslmed.3002807.
2
Rational design of a meningococcal antigen inducing broad protective immunity.脑膜炎球菌抗原的合理设计诱导广泛的保护性免疫。
Sci Transl Med. 2011 Jul 13;3(91):91ra62. doi: 10.1126/scitranslmed.3002234.
3
Vaccines, reverse vaccinology, and bacterial pathogenesis.疫苗、反向疫苗学和细菌发病机制。
Cold Spring Harb Perspect Med. 2013 May 1;3(5):a012476. doi: 10.1101/cshperspect.a012476.
4
Novel approaches to Neisseria meningitidis vaccine design.脑膜炎奈瑟菌疫苗设计的新方法。
Pathog Dis. 2017 Apr 1;75(3). doi: 10.1093/femspd/ftx033.
5
The Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment.核苷酸序列分析对脑膜炎球菌疫苗开发和评估的影响。
Front Immunol. 2019 Jan 15;9:3151. doi: 10.3389/fimmu.2018.03151. eCollection 2018.
6
Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.用源自异源脑膜炎奈瑟菌菌株制备的囊泡进行序贯免疫可引发针对B群菌株的广泛保护性血清抗体。
Infect Immun. 2002 Nov;70(11):6021-31. doi: 10.1128/IAI.70.11.6021-6031.2002.
7
Reverse vaccinology, a genome-based approach to vaccine development.反向疫苗学，一种基于基因组的疫苗开发方法。
Vaccine. 2001 Mar 21;19(17-19):2688-91. doi: 10.1016/s0264-410x(00)00554-5.
8
Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.因子 H 结合蛋白在脑膜炎奈瑟菌毒力中的作用及其作为广泛预防脑膜炎球菌病疫苗候选物的潜力。
Microbiol Mol Biol Rev. 2013 Jun;77(2):234-52. doi: 10.1128/MMBR.00056-12.
9
Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules.基于结构的宿主和病原体分子修饰的脑膜炎球菌疫苗的设计和评估。
PLoS Pathog. 2012;8(10):e1002981. doi: 10.1371/journal.ppat.1002981. Epub 2012 Oct 25.
10
The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.利用反向疫苗学开发 B 型脑膜炎球菌疫苗。
Front Immunol. 2019 Apr 16;10:751. doi: 10.3389/fimmu.2019.00751. eCollection 2019.
引用本文的文献
1
Structure-based vaccines provide protection in a mouse model of ehrlichiosis.基于结构的疫苗在埃立克体病的小鼠模型中提供保护。
PLoS One. 2011;6(11):e27981. doi: 10.1371/journal.pone.0027981. Epub 2011 Nov 17.
本文引用的文献
1
Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus.设计并鉴定展示呼吸道合胞病毒 motavizumab 表位的抗原表位支架免疫原。
J Mol Biol. 2011 Jun 24;409(5):853-66. doi: 10.1016/j.jmb.2011.04.044. Epub 2011 Apr 27.
2
Structure of the uncomplexed Neisseria meningitidis factor H-binding protein fHbp (rLP2086).未复合的脑膜炎奈瑟菌因子H结合蛋白fHbp（rLP2086）的结构
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 May 1;67(Pt 5):531-5. doi: 10.1107/S1744309111006154. Epub 2011 Apr 20.
3
Elicitation of structure-specific antibodies by epitope scaffolds.表位支架诱导结构特异性抗体。
Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17880-7. doi: 10.1073/pnas.1004728107. Epub 2010 Sep 27.
4
Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.基于表位支架的计算设计可诱导针对 HIV 疫苗弱免疫原性表位的特异性抗体。
Structure. 2010 Sep 8;18(9):1116-26. doi: 10.1016/j.str.2010.06.010.
5
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.包膜的合理设计鉴定出针对 HIV-1 的广泛中和人源单克隆抗体。
Science. 2010 Aug 13;329(5993):856-61. doi: 10.1126/science.1187659. Epub 2010 Jul 8.
6
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.抗体 VRC01 广谱且强效中和 HIV-1 的结构基础。
Science. 2010 Aug 13;329(5993):811-7. doi: 10.1126/science.1192819. Epub 2010 Jul 8.
7
Complement control protein factor H: the good, the bad, and the inadequate.补体控制蛋白因子 H：好的、坏的和不足的。
Mol Immunol. 2010 Aug;47(13):2187-97. doi: 10.1016/j.molimm.2010.05.007.
8
Review of meningococcal group B vaccines.脑膜炎 B 型球菌疫苗综述。
Clin Infect Dis. 2010 Mar 1;50 Suppl 2(S2):S54-65. doi: 10.1086/648966.
9
Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection.B 群脑膜炎球菌疫苗抗原对脑膜炎奈瑟菌体外和体内及感染的离体和体内模型中的生长和存活的影响。
Vaccine. 2010 Mar 11;28(12):2416-27. doi: 10.1016/j.vaccine.2009.12.082. Epub 2010 Jan 10.
10
Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.HIV-1 抗体 2F5 的中和作用与其重链第三互补决定区疏水性之间的关系。
J Virol. 2010 Mar;84(6):2955-62. doi: 10.1128/JVI.02257-09. Epub 2009 Dec 30.
Zotero 插件